Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Rating) fell 2.7% on Tuesday . The stock traded as low as $3.68 and last traded at $4.00. 186,214 shares were traded during trading, a decline of 77% from the average session volume of 807,911 shares. The stock had previously closed at $4.11.

Analyst Ratings Changes

Separately, EF Hutton Acquisition Co. I initiated coverage on shares of Werewolf Therapeutics in a research report on Monday, December 5th. They set a "buy" rating and a $8.30 price target on the stock.

Werewolf Therapeutics Stock Down 2.7 %

The stock's 50-day simple moving average is $2.41 and its 200 day simple moving average is $3.84. The company has a market cap of $123 million, a price-to-earnings ratio of -1.86 and a beta of -0.86.

Insider Transactions at Werewolf Therapeutics

In other Werewolf Therapeutics news, Director Ra Capital Management, L.P. purchased 1,853,000 shares of Werewolf Therapeutics stock in a transaction dated Friday, January 6th. The shares were acquired at an average price of $2.21 per share, with a total value of $4,095,130.00. Following the completion of the transaction, the director now owns 5,701,056 shares of the company's stock, valued at $12,599,333.76. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 62.70% of the company's stock.

Institutional Trading of Werewolf Therapeutics

Several hedge funds have recently made changes to their positions in the business. Y Intercept Hong Kong Ltd purchased a new stake in shares of Werewolf Therapeutics during the second quarter worth approximately $45,000. Bailard Inc. purchased a new position in Werewolf Therapeutics in the second quarter valued at approximately $87,000. Millennium Management LLC increased its stake in Werewolf Therapeutics by 487.1% in the second quarter. Millennium Management LLC now owns 248,917 shares of the company's stock valued at $1,018,000 after purchasing an additional 206,516 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Werewolf Therapeutics by 5.5% in the first quarter. Bank of New York Mellon Corp now owns 68,338 shares of the company's stock valued at $301,000 after purchasing an additional 3,555 shares during the last quarter. Finally, Evercore Wealth Management LLC increased its stake in Werewolf Therapeutics by 116.3% in the first quarter. Evercore Wealth Management LLC now owns 46,500 shares of the company's stock valued at $205,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors and hedge funds own 68.17% of the company's stock.

About Werewolf Therapeutics

(Get Rating)

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.

Featured Stories

• Get a free copy of the StockNews.com research report on Werewolf Therapeutics (HOWL)
• Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
• Dividend King Sysco: Buying On The Dip
• Is the 1,600% Rise in Genius Group Stock Justified?
• After Further Review, Investors Liked Exxon Mobil's Earnings
• Will Caterpillar Dig Its Way To Another Buying Opportunity?

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.